Work

Abstract 3779: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitors

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-3779

Authors: Nathan A. Brooks, Shuang Chen, Candace Langan, Bryan Perria, Bonita D. Jones, Hai Hu, Mia Lei, Renan Escalante Chong, Wei Zheng, Rowena Almonte-Baldonado, Xiaodong Huang, Robert Stephen Flack, Janice Y. Lee, Kevin Wilson, Anke Klippel, Laurie LeBrun

Institutions: Eli Lilly (United States), Eli Lilly (Australia), Foghorn Therapeutics (United States)

Language: English

Topic: Chromatin Remodeling and Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409689188

Cites:

Cited by: 1

Related to: 10